- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07676786
Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients (EU-PHASE-HD)
Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis
Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.
This prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.
In participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.
The study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Pulmonary hypertension (PH), defined as mean pulmonary arterial pressure (mPAP) >20 mmHg, is increasingly recognized in patients with chronic kidney disease and is particularly prevalent in those with ESKD on maintenance HD.
Despite its prognostic importance, PH remains under-recognized and insufficiently characterized in HD patients. A major limitation of prior studies is the lack of standardized assessment of volume status, which significantly influences pulmonary pressures.
This prospective, multicenter cohort study aims to address this gap by evaluating PH after rigorous volume optimization. The study includes:
- A pretrial volume assessment phase (3 consecutive HD sessions)
- A structured volume correction phase (if needed)
- A main study cohort including only euvolemic patients
- An exploratory subgroup of patients with persistent hypervolemia
Euvolemia is defined using a multimodal approach including clinical examination, bioimpedance spectroscopy, inferior vena cava (IVC) diameter, interdialytic weight gain, blood pressure stability, and lung ultrasound criteria.
The primary objective is to determine the prevalence of PH in euvolemic HD patients. Secondary objectives include characterization of PH phenotypes and identification of clinical, dialysis-related, and echocardiographic predictors.
Right heart catheterization (RHC) is not mandated for all participants. In patients with echocardiographic findings suggestive of PHafter confirmation of euvolemia, RHC may be performed when clinically indicated and separately consented. When available, invasive hemodynamic data will be used to confirm PH and refine phenotype classification.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Stefan N Lujinschi, MD, PhD candidate
- Numéro de téléphone: +40728102643
- E-mail: stefanlujinschi@gmail.com
Lieux d'étude
-
-
-
Bucharest, Roumanie, 022328
- Fundeni Clinical Institute
-
Contact:
- Stefan N Lujinschi, MD, PhD candidate
- Numéro de téléphone: +40728102643
- E-mail: stefanlujinschi@gmail.com
-
Chercheur principal:
- Stefan N Lujinschi, MD, PhD candidate
-
Bucharest, Roumanie, 022322
- Institute for Cardiovascular Diseases C.C. Iliescu
-
Contact:
- Georgiana Olaru, MD
- Numéro de téléphone: +40767805197
- E-mail: dr.georgianaolaru@yahoo.com
-
Chercheur principal:
- Georgiana Olaru, MD
-
Sous-enquêteur:
- Lucian M Predescu, Assist. Prof., MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years.
- End-stage kidney disease on maintenance HD for ≥ 3 months.
- Stable clinical condition (no hospitalization in last 30 days).
- Able and willing to comply with study protocol.
- Provision of written informed consent
Exclusion Criteria:
- Moderate/severe left-sided valvular disease.
- Active pulmonary or cardiac decompensation.
- Persistent hypervolemia after completion of the volume assessment and correction phase
- Inability to undergo echocardiography or bioimpedance assessment.
- Acute infection or inflammatory condition at the time of enrollment.
- Inadequate echocardiographic window preventing reliable assessment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Euvolemic Hemodialysis Cohort
Participants with end-stage kidney disease on maintenance hemodialysis undergo a structured volume assessment (including clinical assessment, bioimpedance spectroscopy, inferior vena cava measurement, lung ultrasound and echocardiography) and, if necessary, a volume optimization phase. The primary study cohort includes patients who meet predefined euvolemia criteria. An exploratory subgroup includes patients with persistent hypervolemia, analyzed separately. Additional invasive evaluation, including right heart catheterization, may be performed only when clinically indicated and is not assigned as a study intervention. |
Participants undergo structured clinical, echocardiographic, and volume status assessments, including bioimpedance spectroscopy, lung ultrasound and inferior vena cava evaluation. Volume optimization measures are applied as part of routine clinical care and are not assigned as experimental interventions. Right heart catheterization may be performed in selected patients when clinically indicated and after specific informed consent, and is not considered a study intervention. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence of Pulmonary Hypertension in Euvolemic Hemodialysis Patients
Délai: At baseline echocardiographic evaluation after confirmation of euvolemia (within 1 week, post-hemodialysis or next day); in participants undergoing clinically indicated right heart catheterization, assessment may occur within 3 months
|
Pulmonary hypertension will be identified based on echocardiographic criteria (systolic pulmonary arterial pressure [sPAP] ≥40 mmHg) after confirmation of euvolemia.
In participants undergoing clinically indicated right heart catheterization, invasive hemodynamic data (mean pulmonary arterial pressure [mPAP] ≥20 mmHg) will be used for confirmation of pulmonary hypertension.
|
At baseline echocardiographic evaluation after confirmation of euvolemia (within 1 week, post-hemodialysis or next day); in participants undergoing clinically indicated right heart catheterization, assessment may occur within 3 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pulmonary Hypertension Phenotype Distribution
Délai: At baseline echocardiography after euvolemia (within 1 week, post-hemodialysis or next day); in participants with clinically indicated right heart catheterization, assessment may occur within 3 months
|
Distribution of pulmonary hypertension phenotypes based on echocardiographic assessment in the overall cohort, with definitive classification based on right heart catheterization in patients undergoing clinically indicated invasive evaluation.
|
At baseline echocardiography after euvolemia (within 1 week, post-hemodialysis or next day); in participants with clinically indicated right heart catheterization, assessment may occur within 3 months
|
|
Predictors of Pulmonary Hypertension
Délai: At baseline evaluation
|
Clinical, laboratory, dialysis-related, vascular access-related, and volume-related variables associated with the presence of pulmonary hypertension
|
At baseline evaluation
|
|
Association Between Vascular Access and Pulmonary Hypertension
Délai: At baseline evaluation
|
Relationship between vascular access type and pulmonary hypertension parameters.
|
At baseline evaluation
|
|
Association Between Volume Status and Pulmonary Hypertension
Délai: At baseline evaluation
|
Association between bioimpedance, inferior vena cava diameter, interdialytic weight gain, and pulmonary hypertension.
|
At baseline evaluation
|
|
Blood Pressure Variability and Pulmonary Hypertension
Délai: At baseline evaluation
|
Relationship between intradialytic blood pressure variability and pulmonary hypertension parameters.
|
At baseline evaluation
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Gener Ismail, Professor, MD, PhD, Fundeni Clinical Institute
- Chercheur principal: Georgiana N Olaru, MD, Institute for Cardiovascular Diseases C.C. Iliescu
- Chaise d'étude: Ioan M Coman, Professor, MD, PhD, Institute for Cardiovascular Diseases C.C. Iliescu
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladie chronique
- Attributs de la maladie
- Maladies des voies respiratoires
- Maladies pulmonaires
- Insuffisance rénale
- Insuffisance rénale chronique
- Hypertension
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Insuffisance rénale chronique
- Hypertension pulmonaire
- Œdème
Autres numéros d'identification d'étude
- 12798 (Autre identifiant: Fundeni Clinical Institute - Ethics Committee)
- EU-PHASE-HD-01 (Autre identifiant: Fundeni Clinical Institute - Adult Nephrology Department)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .